The incretin-based therapeutic landscape has evolved from single-agonist semaglutide (Ozempic/Wegovy) through dual-agonist tirzepatide (Mounjaro) to the triple-agonist retatrutide. This guide provides a scientific comparison for researchers navigating these compounds.
Receptor Pharmacology Comparison
| Receptor | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| GLP-1R | +++ (Full agonist) | ++ (Moderate) | +++ (Full) |
| GIPR | — | +++ (Full) | +++ (Full) |
| Glucagon R | — | — | ++ (Moderate) |
| Designation | Single agonist | Dual agonist | Triple agonist |
Key Clinical Data Comparison
| Endpoint | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Max weight reduction | ~14.9% (STEP 1) | ~22.5% (SURMOUNT-1) | ~24.2% (TRIUMPH-2) |
| HbA1c reduction | ~1.5% | ~2.37% (SURPASS-2) | ~2.4% (TRIUMPH) |
| Trial duration | 68 weeks | 72 weeks | 48 weeks |
| Dose frequency | Once weekly | Once weekly | Once weekly |
| Half-life | ~7 days | ~5 days | ~6 days |
Mechanistic Differences
Semaglutide — Pure GLP-1 Agonism
Semaglutide is a 31-amino-acid GLP-1 analogue with a C18 fatty acid chain for albumin binding (half-life ~7 days). Its mechanism is restricted to GLP-1 receptor activation: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite suppression. Semaglutide has the most extensive clinical safety database, but its mechanism is the simplest — offering only the GLP-1 component of incretin biology.
Tirzepatide — Dual GIP/GLP-1
Tirzepatide adds GIP receptor activation to the GLP-1 mechanism. GIP agonism provides additional insulinotropic effects and may contribute to energy expenditure pathways. The synergistic effect produces ~50% greater weight reduction than semaglutide in head-to-head comparisons (SURPASS-2). The C20 fatty diacid chain enables once-weekly dosing.
Retatrutide — Triple GIP/GLP-1/Glucagon
Retatrutide adds glucagon receptor activation to the dual-agonist platform. Glucagon agonism drives hepatic fatty acid oxidation, ketogenesis, and brown adipose tissue thermogenesis — directly increasing energy expenditure. This triple mechanism is hypothesised to account for retatrutide's advantage over tirzepatide in weight reduction outcomes.
Research Applications by Compound
- Semaglutide: Well-characterised comparator for GLP-1R-specific research; established dose-response data across metabolic indices.
- Tirzepatide: Best tool for studying GIP/GLP-1 synergy in metabolic and body weight regulation; intermediate between single and triple agonists.
- Retatrutide: Most advanced platform for studying three-receptor pharmacology, energy expenditure mechanisms, and maximal metabolic intervention.
Which to Choose for Research?
The choice depends on the research question. For GLP-1R-specific pharmacology, semaglutide is the established standard. For dual-incretin synergy studies in metabolic research, tirzepatide is the appropriate tool. For comprehensive metabolic research investigating the role of glucagon-driven energy expenditure alongside incretin effects, retatrutide represents the most complete tool.
This comparison is provided for research purposes only. All compounds are for laboratory use.
Element42 Peptides — Retatrutide | Tirzepatide | All products